The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for an intravenous formulation of GlaxoSmithKline’s Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus.
The preliminary decision, outlined in an appraisal consultation document, relates to use of the drug in people aged five years and older when there is a high degree of disease activity (for example, positive anti-double-stranded DNA, low complement) and despite standard therapy, as per its marketing authorisation.
According to NICE, while clinical trial evidence suggests that after a year of treatment Benlysta plus standard therapy reduces disease activity more than standard therapy alone, “the results are uncertain because the trials were short”.
Also, it noted that the long-term benefit of Benlysta compared with standard therapy or rituximab is unknown, as long-term extension studies did not have comparator arms.
Cost-effectiveness estimates are also uncertain, and are most likely higher than what is normally considers an acceptable use of NHS resources, the Institute said.
The consultation is open until June 25 for comments.
Rice water, rich in inositol, antioxidants, vitamins, and minerals, protects hair from sunlight damage and…
Natural Remedies for Bloating: 8 Herbs and Supplements That Work Wonders for Your Gut Health…
Benefits of Oil Pulling: Stops Bad Breath, Keeps Gums Healthy, But Can't Replace Brushing Oil…
Spicy food – whether it’s a dash of chili in your curry, a spoonful of…
How To Identify Adulterated Wheat Flour? Try These 4 Easy Tests Wheat flour is a…
Reasons That Will Make You Eat Jaggery After Every Meal (Potential Health Benefits Inside) Jaggery,…